Skip to main content

Advertisement

SpringerLink
Log in

Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Idiopathic thrombotic thrombocytopenic purpura (TTP) occurs primarily due to the formation of autoantibody against ADAMTS13, a specific von Willebrand factor-cleaving protease, resulting in low ADAMTS13 activity and subsequent accumulation of large vWF multimers, platelet aggregation and thrombus formation in the microvasculature of tissues. Limited clinical data suggest that the administration of anti-CD20 antibody (rituximab) may be useful in treating acute refractory or chronic relapsing idiopathic TTP. We carried out a systematic review with pooled data analysis using individual patient data to evaluate the efficacy of rituximab in these settings. Fifteen case series and 16 case reports comprising 100 patients were eligible for the study. Median age was 39 years. Male constituted 31 % and female 69 %. Complete remission was seen in 98 %, non-response in 2 % and relapse after complete remission in 9 %. For patients with complete remission, median follow-up was 13 months. Median platelet recovery from the first dose of rituximab was 14 days. ADAMTS13 inhibitor positivity and severe ADAMTS13 deficiency were highly predictive of the response to rituximab, implying that these can be useful markers in predicting response to rituximab in acute refractory or chronic relapsing idiopathic TTP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Remuzzi G (1987) HUS and TTP: variable expression of a single entity. Kidney Int 32(2):292–308

    Article  PubMed  CAS  Google Scholar 

  2. Ridolfi RL, Hutchins GM, Bell WR (1979) The heart and cardiac conduction system in thrombotic thrombocytopenic purpura. A clinicopathologic study of 17 autopsied patients. Ann Intern Med 91(3):357–363

    PubMed  CAS  Google Scholar 

  3. Bell MD, Barnhart JS Jr, Martin JM (1990) Thrombotic thrombocytopenic purpura causing sudden, unexpected death–a series of eight patients. J Forensic Sci 35(3):601–613

    PubMed  CAS  Google Scholar 

  4. Podolsky SH, Zembowicz A, Schoen FJ, Benjamin RJ, Sonna LA (1999) Massive myocardial necrosis in thrombotic thrombocytopenic purpura: a case report and review of the literature. Arch Pathol Lab Med 123(10):937–940

    PubMed  CAS  Google Scholar 

  5. Moake JL (2002) Thrombotic microangiopathies. N Engl J Med 347(8):589–600

    Article  PubMed  CAS  Google Scholar 

  6. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B (1998) von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339(22):1578–1584

    Article  PubMed  CAS  Google Scholar 

  7. Sadler JE (2008) Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 112(1):11–18

    Article  PubMed  CAS  Google Scholar 

  8. Tsai HM, Lian EC (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339(22):1585–1594

    Article  PubMed  CAS  Google Scholar 

  9. Siddiqui FA, Lian EC (1993) Characterization of platelet agglutinating protein p37 purified from the plasma of a patient with thrombotic thrombocytopenic purpura. Biochem Mol Biol Int 30(2):385–395

    PubMed  CAS  Google Scholar 

  10. Praprotnik S, Blank M, Levy Y, Tavor S, Boffa MC, Weksler B, Eldor A, Shoenfeld Y (2001) Anti-endothelial cell antibodies from patients with thrombotic thrombocytopenic purpura specifically activate small vessel endothelial cells. Int Immunol 13(2):203–210

    Article  PubMed  CAS  Google Scholar 

  11. Schultz DR, Arnold PI, Jy W, Valant PA, Gruber J, Ahn YS, Mao FW, Mao WW, Horstman LL (1998) Anti-CD36 autoantibodies in thrombotic thrombocytopenic purpura and other thrombotic disorders: identification of an 85 kD form of CD36 as a target antigen. Br J Haematol 103(3):849–857

    Article  PubMed  CAS  Google Scholar 

  12. Mitra D, Jaffe EA, Weksler B, Hajjar KA, Soderland C, Laurence J (1997) Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells. Blood 89(4):1224–1234

    PubMed  CAS  Google Scholar 

  13. von Baeyer H (2002) Plasmapheresis in thrombotic microangiopathy-associated syndromes: review of outcome data derived from clinical trials and open studies. Ther Apher 6(4):320–328

    Article  Google Scholar 

  14. Amorosi EL, Ultmann JE (1966) Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine (Baltimore) 45:139–159

    Google Scholar 

  15. Wyllie BF, Garg AX, Macnab J, Rock GA, Clark WF (2006) Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome: a new index predicting response to plasma exchange. Br J Haematol 132(2):204–209

    Article  PubMed  CAS  Google Scholar 

  16. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 325(6):393–397

    Article  PubMed  CAS  Google Scholar 

  17. Shumak KH, Rock GA, Nair RC (1995) Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Canadian Apheresis Group. Ann Intern Med 122(8):569–572

    PubMed  CAS  Google Scholar 

  18. Bell WR (1997) Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome relapse: frequency, pathogenesis, and meaning. Semin Hematol 34(2):134–139

    PubMed  CAS  Google Scholar 

  19. Ferrara F, Annunziata M, Pollio F, Palmieri S, Copia C, Mele G, Pocali B, Schiavone EM (2002) Vincristine as treatment for recurrent episodes of thrombotic thrombocytopenic purpura. Ann Hematol 81(1):7–10

    Article  PubMed  CAS  Google Scholar 

  20. Bobbio-Pallavicini E, Porta C, Centurioni R, Gugliotta L, Vianelli N, Tacconi F, Billio A, Ascari E (1994) Vincristine sulfate for the treatment of thrombotic thrombocytopenic purpura refractory to plasma-exchange. The Italian Cooperative Group for TTP. Eur J Haematol 52(4):222–226

    Article  PubMed  CAS  Google Scholar 

  21. Cataland SR, Jin M, Ferketich AK, Kennedy MS, Kraut EH, George JN, Wu HM (2007) An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Br J Haematol 136(1):146–149

    Article  PubMed  CAS  Google Scholar 

  22. Cataland SR, Jin M, Lin S, Kennedy MS, Kraut EH, George JN, Wu HM (2007) Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity. Br J Haematol 139(3):486–493

    Article  PubMed  CAS  Google Scholar 

  23. Agarwal V, Sharma BL, Aggarwal A, Misra R (2002) Does cyclophosphamide benefit relapsing thrombotic thrombocytopenic purpura? J Assoc Physicians India 50:1440–1442

    PubMed  CAS  Google Scholar 

  24. Hertzberg MS, Koutts J (1997) Oral cyclophosphamide for refractory or relapsing thrombotic thrombocytopenic purpura (TTP). Aust N Z J Med 27(4):439

    Article  PubMed  CAS  Google Scholar 

  25. Zappasodi P, Corso A, Castagnola C, Tajana M, Lunghi M, Bernasconi C (1999) A successful combination of plasma exchange and intravenous cyclophosphamide in a patient with a refractory thrombotic thrombocytopenic purpura. Eur J Haematol 63(4):278–279

    Article  PubMed  CAS  Google Scholar 

  26. Moake JL, Rudy CK, Troll JH, Schafer AI, Weinstein MJ, Colannino NM, Hong SL (1985) Therapy of chronic relapsing thrombotic thrombocytopenic purpura with prednisone and azathioprine. Am J Hematol 20(1):73–79

    Article  PubMed  CAS  Google Scholar 

  27. Aqui NA, Stein SH, Konkle BA, Abrams CS, Strobl FJ (2003) Role of splenectomy in patients with refractory or relapsed thrombotic thrombocytopenic purpura. J Clin Apher 18(2):51–54

    Article  PubMed  Google Scholar 

  28. Kappers-Klunne MC, Wijermans P, Fijnheer R, Croockewit AJ, van der Holt B, de Wolf JT, Lowenberg B, Brand A (2005) Splenectomy for the treatment of thrombotic thrombocytopenic purpura. Br J Haematol 130(5):768–776

    Article  PubMed  CAS  Google Scholar 

  29. Ahmad A, Aggarwal A, Sharma D, Dave HP, Kinsella V, Rick ME, Schechter GP (2004) Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP). Am J Hematol 77(2):171–176

    Article  PubMed  CAS  Google Scholar 

  30. Albaramki JH, Teo J, Alexander SI (2009) Rituximab therapy in two children with autoimmune thrombotic thrombocytopenic purpura. Pediatr Nephrol 24(9):1749–1752

    Article  PubMed  Google Scholar 

  31. Chemnitz J, Draube A, Scheid C, Staib P, Schulz A, Diehl V, Sohngen D (2002) Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am J Hematol 71(2):105–108

    Article  PubMed  CAS  Google Scholar 

  32. Chemnitz JM, Uener J, Hallek M, Scheid C (2010) Long-term follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab. Ann Hematol 89(10):1029–1033

    Article  PubMed  CAS  Google Scholar 

  33. Dalia S, McNulty B, Colvin GA (2008) Rituximab in treating refractory thrombotic thrombocytopenic purpura: three case reports. Med Health R I 91(7):226–228

    PubMed  Google Scholar 

  34. Elliott MA, Heit JA, Pruthi RK, Gastineau DA, Winters JL, Hook CC (2009) Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature. Eur J Haematol 83(4):365–372

    Article  PubMed  CAS  Google Scholar 

  35. Fakhouri F, Vernant J-P, Veyradier A, Wolf M, Kaplanski G, Binaut R, Rieger M, Scheiflinger F, Poullin P, Deroure B, Delarue R, Lesavre P, Vanhille P, Hermine O, Remuzzi G, Grunfeld J-P (2005) Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 106(6):1932–1937

    Article  PubMed  CAS  Google Scholar 

  36. Gutterman LA, Kloster B, Tsai H-M (2002) Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells Mol Dis 28(3):385–391

    Article  PubMed  Google Scholar 

  37. Koulova L, Alexandrescu D, Dutcher JP, O’Boyle KP, Eapen S, Wiernik PH (2005) Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases. Am J Hematol 78(1):49–54

    Article  PubMed  CAS  Google Scholar 

  38. Ling HT, Field JJ, Blinder MA (2009) Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature. Am J Hematol 84(7):418–421

    Article  PubMed  CAS  Google Scholar 

  39. Patino W, Sarode R (2007) Successful repeat therapy with rituximab for relapsed thrombotic thrombocytopenic purpura. J Clin Apheresis 22(1):17–20

    Article  PubMed  Google Scholar 

  40. Reddy PS, Deauna-Limayo D, Cook JD, Ganguly SS, Blecke C, Bodensteiner DC, Skikne BS, Sahud MA (2005) Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura. Ann Hematol 84(4):232–235

    Article  PubMed  CAS  Google Scholar 

  41. Sallah S, Husain A, Wan JY, Nguyen NP (2004) Rituximab in patients with refractory thrombotic thrombocytopenic purpura. J Thromb Haemost 2(5):834–836

    Article  PubMed  CAS  Google Scholar 

  42. Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S, Mackie I, Machin SJ (2007) Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol 136(3):451–461

    Article  PubMed  CAS  Google Scholar 

  43. Lombardi AM, de Marinis GB, Scandellari R, Magalini F, Sansoni P, Ballerini PF, Vettore S, Candeo N, Marson P, De Silvestro G, Fabris F (2010) Clinical biological remission induced by rituximab in acute refractory chronic relapsing TTP. Thromb Res 126(2):e154–e156

    Article  PubMed  CAS  Google Scholar 

  44. Basquiera AL, Damonte JC, Abichain P, Sturich AG, Garcia JJ (2008) Long-term remission in a patient with refractory thrombotic thrombocytopenic purpura treated with rituximab and plasma exchange. Ann Hematol 87(4):321–323

    Article  PubMed  CAS  Google Scholar 

  45. Hull MJ, Eichbaum QG (2006) Efficacy of rituximab and concurrent plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Clin Adv Hematol Oncol 4(3):210–214 discussion 217–218

    PubMed  Google Scholar 

  46. Jayabose S, Dunbar J, Nowicki TS, Tugal O, Ozkaynak MF, Sandoval C (2011) Rituximab therapy to prevent relapse in chronic relapsing thrombotic thrombocytopenic purpura (TTP) in a child. Pediatr Hematol Oncol 28(2):167–172

    Article  PubMed  CAS  Google Scholar 

  47. Kosugi S, Matsumoto M, Ohtani Y, Take H, Ishizashi H, Fujimura Y, Kuyama J (2005) Rituximab provided long-term remission in a patient with refractory relapsing thrombotic thrombocytopenic purpura. Int J Hematol 81(5):433–436

    Article  PubMed  Google Scholar 

  48. Mak SK, Lo KY, Lo MW, Chan SF, Lo KC, Wong YY, Tong GMW, Wong PN, Ma ESK, Wong AKM (2009) Refractory thrombotic thrombocytopenic purpura and membranoproliferative glomerulonephritis successfully treated with rituximab: a case associated with hepatitis C virus infection. Hong Kong Med 15(3):201–208

    CAS  Google Scholar 

  49. Millward PM, Bandarenko N, Chang PP, Stagg KF, Afenyi-Annan A, Hay SN, Brecher ME (2005) Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab. Transfusion 45(9):1481–1486

    Article  PubMed  CAS  Google Scholar 

  50. Ojeda-Uribe M, Federici L, Wolf M, Coppo P, Veyradier A (2010) Successful long-term rituximab maintenance for a relapsing patient with idiopathic thrombotic thrombocytopenic purpura [Erratum appears in Transfusion. 2010 May;50(5):1159]. Transfusion 50(3):733–735

    Article  PubMed  Google Scholar 

  51. Kuppachi S, Chander P, Yoo J (2009) Membranous nephropathy and thrombotic thrombocytopenic purpura treated with rituximab. J Nephrol 22(4):561–564

    PubMed  Google Scholar 

  52. Rufer A, Brodmann D, Gregor M, Kremer Hovinga JA, Lammle B, Wuillemin WA (2007) Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura. A case report and concise review of the literature. Swiss Med Wkly 137(37-38):518–524

    PubMed  CAS  Google Scholar 

  53. Stein GY, Zeidman A, Fradin Z, Varon M, Cohen A, Mittelman M (2004) Treatment of resistant thrombotic thrombocytopenic purpura with rituximab and cyclophosphamide. Int J Hematol 80(1):94–96

    Article  PubMed  Google Scholar 

  54. Tsai H-M, Shulman K (2003) Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura. Eur J Haematol 70(3):183–185

    Article  PubMed  Google Scholar 

  55. Yomtovian R, Niklinski W, Silver B, Sarode R, Tsai H-M (2004) Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol 124(6):787–795

    Article  PubMed  Google Scholar 

  56. Zheng X, Pallera AM, Goodnough LT, Sadler JE, Blinder MA (2003) Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab [Summary for patients in Ann Intern Med. 2003 Jan 21;138(2):I38; PMID: 12529111]. Ann Intern Med 138(2):105–108

    PubMed  CAS  Google Scholar 

  57. Darabi K, Berg AH (2006) Rituximab can be combined with daily plasma exchange to achieve effective B-cell depletion and clinical improvement in acute autoimmune TTP. Am J Clin Pathol 125(4):592–597

    PubMed  CAS  Google Scholar 

  58. Harambat J, Lamireau D, Delmas Y, Ryman A, Llanas B, Brissaud O (2011) Successful treatment with rituximab for acute refractory thrombotic thrombocytopenic purpura related to acquired ADAMTS13 deficiency: a pediatric report and literature review. Pediatr Crit Care Med 12(2):e90–e93

    Article  PubMed  Google Scholar 

  59. Magalini F, Stella A, Basaglia M, Vescovini R, Sassi M, Maria Lombardi A, Sansoni P (2011) Thrombotic thrombocytopenic purpura with severe neurological impairment: remission after Rituximab. Transfus Med 21(2):140–143

    Article  PubMed  CAS  Google Scholar 

  60. Au W-Y, Ma ES, Lee T-L, Ha S-Y, Fung AT, Lie AKW, Kwong Y-L (2007) Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab. Br J Haematol 137(5):475–478

    Article  PubMed  CAS  Google Scholar 

  61. Castagna L, Todisco E, Sarina B, Santoro A (2007) Rituximab in thrombotic microangiopathy. British J Haematol 139(1):166–167 author reply 166–167

    Article  Google Scholar 

  62. Carella AM, D’Arena G, Greco MM, Nobile M, Cascavilla N (2008) Rituximab for allo-SCT-associated thrombotic thrombocytopenic purpura. Bone Marrow Transpl 41(12):1063–1065

    Article  CAS  Google Scholar 

  63. Evans MW, Vaughan LB, Giffi VS, Zimrin AB, Hess JR (2010) Rituximab treatment for thrombotic thrombocytopenic purpura associated with human immunodeficiency virus failing extensive treatment with plasma exchange: a report of two cases. AIDS Patient Care STDS 24(6):349–352

    Article  PubMed  Google Scholar 

  64. Kameda T, Dobashi H, Kittaka K, Susaki K, Yamaoka G, Arai K, Tokuda M, Ishida T (2007) Two cases of refractory thrombotic thrombocytopenic purpura associated with collagen vascular disease were significantly improved by rituximab treatment. Clin Rheumatol 26(12):2159–2162

    Article  PubMed  Google Scholar 

  65. Asamiya Y, Moriyama T, Takano M, Iwasaki C, Kimura K, Ando Y, Aoki A, Kikuchi K, Takei T, Uchida K, Nitta K (2010) Successful treatment with rituximab in a patient with TTP secondary to severe ANCA-associated vasculitis. Intern Med 49(15):1587–1591

    Article  PubMed  Google Scholar 

  66. Gallerani E, Lerch E, Romagnani E, Stathis A, Giardelli G, Zwhalen H, Marone C, Cavalli F (2006) Thrombotic thrombocytopenic purpura associated with renal failure after autologous transplantation for multiple myeloma successfully treated with rituximab. Eur J Haematol 77(6):527–529

    Article  PubMed  Google Scholar 

  67. Gourley BL, Mesa H, Gupta P (2010) Rapid and complete resolution of chemotherapy-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) with rituximab. Cancer Chemother Pharmacol 65(5):1001–1004

    Article  PubMed  CAS  Google Scholar 

  68. Gupta D, Roppelt H, Bowers B, Kunz D, Natarajan M, Gruber B (2008) Successful remission of thrombotic thrombocytopenic purpura with rituximab in a patient with undifferentiated connective tissue disorder. J Clin Rheumatol 14(2):94–96

    Article  PubMed  Google Scholar 

  69. Halim AG, Soehardy Z, Shahrir, Rozita M, Loo CY, Rashidi S, Norella Kong CT (2008) Rituximab in recalcitrant thrombotic thrombocytopenic purpura secondary to systemic lupus erythematosus. Int J Rheum Dis 11(1):69–72

    Article  Google Scholar 

  70. Hong MJ, Lee HG, Hur M, Kim SY, Cho YH, Yoon SY (2011) Slow, but complete, resolution of mitomycin-induced refractory thrombotic thrombocytopenic purpura after rituximab treatment. Korean J Hematol 46(1):45–48

    Article  PubMed  Google Scholar 

  71. Hundae A, Peskoe S, Grimsley E, Patel S (2008) Rituximab therapy for refractory thrombotic thrombocytopenic purpura and autoimmune-mediated thrombocytopenia in systemic lupus erythematosus. South Med J 101(9):943–944

    Article  PubMed  Google Scholar 

  72. Kamiya K, Kurasawa K, Arai S, Maezawa R, Hanaoka R, Kumano K, Fukuda T (2010) Rituximab was effective on refractory thrombotic thrombocytopenic purpura but induced a flare of hemophagocytic syndrome in a patient with systemic lupus erythematosus. Mod Rheumatol 20(1):81–85

    Article  PubMed  Google Scholar 

  73. Limal N, Cacoub P, Sene D, Guichard I, Piette JC (2008) Rituximab for the treatment of thrombotic thrombocytopenic purpura in systemic lupus erythematosus. Lupus 17(1):69–71

    Article  PubMed  CAS  Google Scholar 

  74. Niaz FA, Aleem A (2010) Response to rituximab in a refractory case of thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus. Saudi J Kidney Dis Transpl 21(1):109–112

    PubMed  Google Scholar 

  75. Onitilo AA, Engel JM, Clouse LH, Gerndt KM (2009) Successful treatment of mitomycin-induced thrombotic thrombocytopenic purpura with rituximab. J Vasc Interv Radiol 20(2):275–276

    Article  PubMed  Google Scholar 

  76. Pieringer H, Schmekal B, Gruber F, Vosko MR, Biesenbach G (2009) Transient hemolytic anemia after kidney transplantation and thrombotic thrombocytopenic purpura refractory to plasma exchange and rituximab. Ren Fail 31(5):419–420

    Article  PubMed  Google Scholar 

  77. Ross CL, Hunt BJ, Wyncoll D, Hodgkiss A, Peters B (2009) HIV, thrombotic thrombocytopaenic purpura and rituximab in a violent noncompliant patient. Blood Coagul Fibrinolysis 20(2):157–160

    Article  PubMed  CAS  Google Scholar 

  78. Ruiz J, Koduri PR, Valdivieso M, Shah PC (2005) Refractory post-pancreatitis thrombotic thrombocytopenic purpura: response to rituximab. Ann Hematol 84(4):267–268

    Article  PubMed  Google Scholar 

  79. Benetatos L, Vassou A, Bourantas KL (2006) Effectiveness of rituximab as prophylaxis in thrombotic thrombocytopenic purpura. Clin Lab Haematol 28(4):288–289

    Article  PubMed  CAS  Google Scholar 

  80. Tripodi A, Chantarangkul V, Bohm M, Budde U, Dong JF, Friedman KD, Galbusera M, Girma JP, Moake J, Rick ME, Studt JD, Turecek PL, Mannucci PM (2004) Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas. J Thromb Haemost 2(9):1601–1609. doi:10.1111/j.1538-7836.2004.00879.x

    Article  PubMed  CAS  Google Scholar 

  81. Scheiflinger F, Knobl P, Trattner B, Plaimauer B, Mohr G, Dockal M, Dorner F, Rieger M (2003) Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood 102(9):3241–3243

    Article  PubMed  CAS  Google Scholar 

  82. Shelat SG, Smith P, Ai J, Zheng XL (2006) Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo. J Thromb Haemost 4(8):1707–1717

    Article  PubMed  CAS  Google Scholar 

  83. Rose M, Eldor A (1987) High incidence of relapses in thrombotic thrombocytopenic purpura. Clinical study of 38 patients. Am J Med 83(3):437–444

    Article  PubMed  CAS  Google Scholar 

  84. Ozdogu H, Boga C, Kizilkilic E, Yeral M, Kozanoglu I, Karatas M (2007) A dramatic response to rituximab in a patient with resistant thrombotic thrombocytopenic purpura (TTP) who developed acute stroke. J Thromb Thrombolysis 23(2):147–150

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Division of Hematology and Oncology, The Brooklyn Hospital Center, 121 Dekalb Avenue, Brooklyn, NY, 11220, USA

    Nay M. Tun & Gina M. Villani

Authors
  1. Nay M. Tun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gina M. Villani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nay M. Tun.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tun, N.M., Villani, G.M. Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis. J Thromb Thrombolysis 34, 347–359 (2012). https://doi.org/10.1007/s11239-012-0723-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-012-0723-9

Keywords

Search

Navigation